In this September 6, 2024 Podcast episode by SciPod Health and Medicine, it summarizes the recent paper “Lecanemab for Patients with Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial” by Dr. Donald Berry and Dr. Scott Berry.
In addition, it describes the benefit and success of adaptive clinical trial design within a Bayesian statistical approach not only within this Eisai Alzheimer trial, but many other trials. One example it highlights in another disease area, is the AWARD-5 trial for Eli Lilly’s type 2 diabetes drug Trulicity that has made it the most successful and profitable drug ever for Eli Lilly.
See the link to the Podcast here: https://www.scipod.global/innovative-clinical-trial-design-via-artificial-intelligence-identifies-effective-drug-and-its-most-efficacious-dose-for-treating-early-alzheimer-disease/